In Section C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Members will get treatment right up until sickness progression or maybe the contributors are unable to tolerate the study drugs. Ubiquitin-similar proteins that control the stability of crucial super enhancer-mediated proteins https://julianx110jvf3.blogripley.com/profile